PennyOmega.com Short Highlights Before the Bell!

PennyOmega.com Short Highlights Before The Bell!

PennyOmega.com Stocks Upgraded, Downgraded and Short Highlights Before the Bell Friday August 7, 2009

**************************************************************

Volcano Corporation (Nadsaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13.

K-Sea Transportation Partners L.P. (NYSE: KSP) announced today that it has priced its previously announced public offering of 2.9 million common units representing limited partner interests at a price to the public of $19.15 per common unit. The offering is scheduled

...

Angiodynamics, Inc. (ANGO) reported fourth quarter and full fiscal year 2009 results and provided guidance for full fiscal year 2010 yesterday after the close of the market. Excluding extraordinary items, the company reported fourth quarter EPS of $0.14, below the Street’s expectations of $0.15. The company also provided guidance for fiscal 2010 below the Street’s expectations. Quarterly results Net sales in the quarter were $52.8 million, an increase of 13% y/y. Growth in net sales can be attributed to higher sales of vein ablation and oncology products, primarily the company’s embolization product, LCB. Peripheral Vascular sales increased 26% y/y to $22.5 million. Growth was primarily due to the acquisition of laser ablation products from Diomed and the Benephit renal infusion system from FlowMedica. Access sales declined 1% y/y to $17.9 million. The decline was due to the withdrawal of the Centros dialysis catheter from the ...

Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.

1.) Angiotech Pharma [ANPI: 1.97, 0.00 (0.00%)] – currently trading at $2.14, market cap = $182 million

ANPI has an FDA-approved dialysis catheter (HemoStream) that is sold through its direct sales

...